Posted by Michael Wonder on 30 Mar 2025
IBT is granted breakthrough therapy designation for its drug candidate
28 March 2025 - The US FDA has granted a breakthrough therapy designation for IBP-9414’s potential to reduce gastrointestinal-related mortality.
IBT is now preparing for the submission in parallel with the activities for the launch of IBP-9414.
